SEC Form 4 · accession 0001193125-26-392319
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Chief Financial Officer
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 9:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000034956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 11, 2026 | P | 5,675 | $1.935 | A | 15,675 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $11.95 | holding | — | — | — | — | May 11, 2036 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.